
Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
Updated analysis of the ABC trials favors anthracycline-based regimens in terms of IDFS and RFI, but no OS, when compared to taxane-based chemotherapy
Encouraging EFS and OS results were presented at an ESMO Virtual Plenary for the use of the immune checkpoint inhibitor prior and after surgery
Survival benefits of the radioligand therapy needs to be confirmed in further studies
Cabozantinib plus atezolizumab may represent a novel option for patients progressing on first-line hormonal therapy
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
ESR1 variants show to be predictive of response to fulvestrant and novel mutations have been identified
A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.